Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tissue Regenix Ltd.

This article was originally published in Start Up

Executive Summary

Tissue Regenix is developing what it describes as "de-cellularized biological scaffolds," which are meant to function like native tissue. Tissue Regenix uses tissue taken from pigs or cows as its starting material, then carefully strips out cells, leaving behind a complex matrix of proteins such as collagen and elastin. Once this matrix is implanted, the body's own cells go into it and encourage cell recruitment and tissue formation.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel